愛滋病暴露前預防性投藥之藥物新進展

10.6666/ClinMed.202409_94(3).0102

謝尚融；陳伯亮；黃鈴茹

人類免疫缺乏病毒（human immunodeficiency virus, HIV） ； 暴露前預防性投藥（pre-exposure prophylaxis, PrEP）

臨床醫學月刊

94卷3期（2024 / 09 / 27）

584 - 590

繁體中文

暴露前預防性投藥（pre-exposure prophylaxis, PrEP）為預防人類免疫缺乏病毒（human immunodeficiency virus, HIV）感染的重要手段，臺灣從2016年起於指定醫事機構開始提供公費與自費PrEP服務，目前已進入第三次全國公費PrEP計畫，而HIV新發生感染者人數自2017年高峰後一路降低。Tenofovir disoproxil fumarate/Emtricitabine（TDF/FTC）為第一個被臺灣食品藥物管理局核可使用的藥物，惟其具影響腎功能與骨質疏鬆之副作用。近期臨床試驗指出TAF/FTC具有更少腎功能影響以及骨質疏鬆副作用，而長效針劑Cabotegravir long-acting（CAB-LA）則顯示相較TDF/FTC更方便的HIV預防效果，可提供風險者更多元的HIV預防方式。

1. UNAIDS. In Danger: UNAIDS Global AIDS Update 2022. Geneva: UNAIDS 2022.
   連結：
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
   連結：
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
   連結：
4. Deutsch MB, Glidden DV, Sevelius J, et al. iPrEx investigators. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx Lancet HIV 2015;2:e512–9.
   連結：
5. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand(the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2013;381:2083-90.
   連結：
6. ayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis(DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The Lancet 2020;396:239-54.
   連結：
7. andovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. New England Journal of Medicine 2021;385:595-608.
   連結：
8. elany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. The Lancet 2022;399:1779-89.
   連結：
9. PTN 084-01. HIV Prevention Trials Network, 2023.< https://www.hptn.org/research/studies/084-01>
   連結：
10. rant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014;14: 820-9.
    連結：
11. arzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis 2021;224:1581-92.
    連結：
12. 025 AIDS TARGETS. UNAIDS, 2023.
    連結：
13. HIV/AIDS in Taiwan. Centers for Disease Control. R.O.C.(Taiwan), 2022. < https://www.cdc.gov.tw/En/Category/ListContent/bg0g_VU_Ysrgkes_KRUDgQ?uaid=CqNo313w78G1fWhz429xDA >
14. WHO. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Geneva: UNAIDS, UNICEF 2011.
15. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization 2015.
16. 暴露愛滋病毒前預防性投藥(PrEP)衛生福利部疾病管制署 2023。
17. 灣愛滋病學會。臺灣暴露前口服預防性投藥使用指引(第二版)。2018。
18. PTN 083-01. HIV Prevention Trials Network 2023.
19. nited States Centers for Disease Control and Prevention. 2021. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States(2021 Update)– Clinical Practice Guideline.
20. 灣愛滋病學會。臺灣暴露前口服預防性投藥使用指引(第三版)。2023。